We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioTek’s Gen5 Software Offers CVB Relative Potency Solution
Product News

BioTek’s Gen5 Software Offers CVB Relative Potency Solution

BioTek’s Gen5 Software Offers CVB Relative Potency Solution
Product News

BioTek’s Gen5 Software Offers CVB Relative Potency Solution


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BioTek’s Gen5 Software Offers CVB Relative Potency Solution"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioTek has announced the availability of customizable pre-programmed protocols for Gen5™ Data Analysis Software designed to estimate Relative Potency according to the requirements of the USDA APHIS Center for Veterinary Biologics (CVB) guidelines published March 14, 2014.

The CVBSOP0101.01 establishes the criteria that veterinary vaccine producers must use to estimate the relative potency of their test serials prior to submission for licensing through the CVB.

Several pre-programmed Gen5 protocols addressing both the full dose response and the linear methods for calculation are available for free download from BioTek’s website.

BioTek’s Gen5 capability provides CVB compliant laboratories with a convenient option to meet the stringent requirements of this SOP.

BioTek will be hosting a webinar on September 25, 2014 where they will describe the use of Gen5 software to estimate relative potency values per the CVB requirements.

Advertisement